PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

Virax Biolabs Group Limited (VRAX) Sharpe Ratio: -0.43

Equity · Currency in USD · Last updated Jul 14, 2026

VRAX's Sharpe Ratio of -0.43 indicates that for each unit of volatility, it generates -0.43 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jul 14, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.

VRAX Sharpe Ratio Rank

VRAX Sharpe Ratio Rank: 24.725
Below Average

VRAX ranks above 24.7% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating below-average returns relative to volatility. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Returns may not adequately compensate for volatility taken
  • Consider smaller allocation given below-average risk-adjusted profile
  • Explore higher-ranked investments with better consistency
  • Assess whether the volatility profile aligns with your portfolio goals

VRAX Sharpe Ratio Market Positioning

The chart shows VRAX's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.

  • Red zone (bottom 25%): -0.45 or lower
  • Yellow zone (middle 50%): -0.45 to 0.96
  • Green zone (top 25%): 0.96 or higher
  • Top 1%: 4.51+
  • Median: 0.11 — half of all investments score higher

How it compares to other similar stocks

The table compares Virax Biolabs Group Limited's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how VRAX's risk-adjusted performance compares to industry peers.

Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jul 14, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
RVMDWRevolution Medicines Inc. Warrant15.11
ERASErasca, Inc.10.99
CLYMClimb Bio Inc8.88
RLMDRelmada Therapeutics, Inc.8.18
SLGLSol-Gel Technologies Ltd.8.13
ANROAlto Neuroscience, Inc7.70
SYRESpyre Therapeutics Inc.7.22
DRTSWAlpha Tau Medical Ltd. Warrant6.85
STTKShattuck Labs, Inc.6.81
ORKAOruka Therapeutics, Inc6.46
VRAXVirax Biolabs Group Limited-0.43

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows VRAX's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when VRAX consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does VRAX fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio